title: A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction.
abstract: OBJECTIVE
  To summarize and quantify results of echocardiographic studies examining the effect of angiotensin converting enzyme (ACE) inhibition on left ventricular remodelling in patients with acute myocardial infarction (MI) and in patients with left ventricular systolic dysfunction (LVSD).
  
  
  METHODS
  Systematic review of the literature and meta-analysis of eligible studies providing data on end-diastolic and end-systolic volumes and left ventricular ejection fraction (LVEF) were performed.
  
  
  RESULTS
  Data from 16 eligible studies were meta-analysed. The results of studies including patients with MI and preserved LVEF (>45%) showed no significant benefit of ACE inhibition. Results of studies/subgroups with mean LVEF < or =45% demonstrated significant differences in diastolic and systolic volumes of 3.0 (0.1, 6.0) ml and 2.25 (0.04, 4.4) ml in short-term (4-14 weeks) follow-up in favour of ACE inhibitor, p=0.041 and p=0.046 respectively. In the long-term (6-12 months) follow-up, the differences in diastolic and systolic volumes were 4.2 (0.98, 7.4) ml and 3.3 (0.9, 5.8) ml in favour of ACE inhibitor, p=0.01 and p=0.007 respectively. LVEF improved in both short and long-term follow-up, p=0.034 and p=0.021, respectively.
  
  
  CONCLUSIONS
  Chronic use of ACE inhibition has a small but sustained and beneficial effect on remodelling in patients with myocardial infarction and patients with chronic left ventricular dysfunction.
authors.affiliation: Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark. ja@heart.dk
authors.forename: Jawdat
authors.initials: J
authors.lastname: Abdulla
authors.forename: Simona
authors.initials: S
authors.lastname: Barlera
authors.forename: Roberto
authors.initials: R
authors.lastname: Latini
authors.forename: Lars
authors.initials: L
authors.lastname: Kjoller-Hansen
authors.forename: Peter
authors.initials: P
authors.lastname: Sogaard
authors.forename: Erik
authors.initials: E
authors.lastname: Christensen
authors.forename: Lars
authors.initials: L
authors.lastname: Kober
authors.forename: Christian
authors.initials: C
authors.lastname: Torp-Pedersen
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002908:Chronic Disease; D003971:Diastole / Q000187:drug effects; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000187:drug effects*; D006801:Humans; D009203:Myocardial Infarction / Q000000981:diagnostic imaging*; D016032:Randomized Controlled Trials as Topic; D013318:Stroke Volume / Q000187:drug effects*; D013599:Systole / Q000187:drug effects; D016896:Treatment Outcome; D014463:Ultrasonography; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000188:drug therapy*; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors